Real World Use of Emicizumab in Infants and Children Ages 0-3 Years With Hemophilia A
- Conditions
- Hemophilia A
- Registration Number
- NCT05248594
- Lead Sponsor
- Montefiore Medical Center
- Brief Summary
We have developed a questionnaire to elucidate the dosing, frequency and indication for the use of emicizumab in patients with Hemophilia A (mild, moderate or severe) ages 0-3 years. We are also collecting data on any pre-, peri and post surgical practices while on emicizumab. More importantly, we are asking if pediatricians are planning to introduce factor 8 to children who are already on emicizumab for primary prophylaxis as well as how and when they are planning to do so. We hope that this data will help inform understanding of current use of emicizumab in infants and young children as a form of primary prophylaxis, especially when venous access has historically been a limiting factor.
- Detailed Description
This will be a multi-institutional, retrospective review of pediatric patients ages 0 to 36 months of age who are currently receiving and/or have received emicizumab-kxwh as part of their treatment for hemophilia A with or without inhibitors. Participating sites are part of the New England Region (plus New Jersey and New York-Region II) of hemophilia treatment centers. Currently 11 out of the 23 regional centers have committed to collaborating on this study (Appendix A). Each institution will be contributing subjects who have been treated or who are currently being treated with emicizumab, from October 4th, 2018 up to the point of IRB approval. Additionally, each institution will determine the best way to identify eligible patients and keep track of patients enrolled in the study. The Children's Hospital at Montefiore will be the coordinating center.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 50
Patients must meet the following criteria for study entry:
- Patients who have been prescribed Emicizumab
- Patients who are 0-36 months of age at the time of starting treatment with Emicizumab
- Diagnosis of congenital mild, moderate or severe hemophilia with or without an inhibitor
- Patients with acquired Hemophilia A
- Patients with Hemophilia A and another congenital or acquired bleeding disorder.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The proportion of patients that are being treated with emicizumab Within a year. The primary outcome will include the proportion of patients that are being treated with emicizumab for primary prophylaxis, as well as identifying breakthrough bleeding while on emicizumab.
- Secondary Outcome Measures
Name Time Method Patients who receive additional doses of factor concentrate while on emicizumab Within a year. Data collected will also include proportion of patients who receive additional doses of factor concentrate while on emicizumab for trauma or surgical interventions.
Trial Locations
- Locations (10)
Connecticut Children's Hemophilia Treatment Center - Connecticut Children's Medical Center
🇺🇸Hartford, Connecticut, United States
Yale Hemophilia Treatment Center
🇺🇸New Haven, Connecticut, United States
Dartmouth Hitchcock Hemophilia Center - Mary Hitchcock Memorial Hospital
🇺🇸Lebanon, New Hampshire, United States
Newark Beth Israel
🇺🇸Newark, New Jersey, United States
Children's Hospital at Montefiore
🇺🇸Bronx, New York, United States
Western NY Blood Care - Research Foundation for SUNY
🇺🇸Buffalo, New York, United States
Comprehensive Center for Hemophilia and Coagulation Disorders (Cornell)
🇺🇸New York, New York, United States
Mary M Gooley Hemophilia Center, Inc.
🇺🇸Rochester, New York, United States
Northwell Health Hemostasis and Thrombosis Center
🇺🇸Staten Island, New York, United States
SUNY Upstate Hemophilia Treatment Center - HTC 058
🇺🇸Syracuse, New York, United States